Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 5, 2013, Pages 686-693

  Chu, Kevin S ^a   Hasan, Warefta ^b   Rawal, Sumit ^a   Walsh, Mark D ^a   Enlow, Elizabeth M ^b   Luft, J Christopher ^a,b   Bridges, Arlene S ^c   Kuijer, Jennifer L ^a   Napier, Mary E ^a,b,c   Zamboni, William C ^a,c,d   DeSimone, Joseph M ^a,b,c,e,f  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d University of North Carolina   (United States)

^e North Carolina State University   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Nanoparticle; Pharmacokinetics; PLGA; Shape; Soft lithography

Indexed keywords

FABRICATION TECHNIQUE; MONONUCLEAR PHAGOCYTE SYSTEMS; OVARIAN CARCINOMA; PLGA; POLY LACTIDE-CO-GLYCOLIDE; SHAPE; SHAPED PARTICLES; SOFT-LITHOGRAPHY;

BIOLOGICAL MATERIALS; MAMMALS; NANOPARTICLES; PHARMACOKINETICS; PLASMAS; TUMORS;

DRUG PRODUCTS;

DOCETAXEL; NANOPARTICLE; POLYETHYLENE TEREPHTHALATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SIZE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LUNG; MONONUCLEAR PHAGOCYTE; MOUSE; NANOFABRICATION; NONHUMAN; OVARY CANCINOMA; OVARY CARCINOMA; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SPLEEN; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; NANOPARTICLES; OVARIAN NEOPLASMS; PARTICLE SIZE; TAXOIDS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84879459400     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.11.008     Document Type: Article

References (33)

1. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
2. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
3. O'Brien M.E.R. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil") versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
4. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
5. Chrastina A., Massey K.A., Schnitzer J.E. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011, 3:421-437.
6. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009, 69:3918-3926.
7. Kim S.C., Kim D.W., Shim Y.H., Bang J.S., Oh H.S., Wan Kim S., et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001, 72:191-202.
8. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000, 60:1197-1201.
9. Doiron A.L., Chu K., Ali A., Brannon-Peppas L. Preparation and initial characterization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI. Proc Natl Acad Sci USA 2008, 105:17232-17237.
10. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008, 105:2586-2591.
11. Farokhzad O., Langer R.S. Nanoparticle delivery of cancer drugs. Annu Rev Med 2011, 63:185-198.
12. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
13. Yoo J.W., Chambers E., Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des 2010, 16:2298-2307.
14. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
15. Chen L.T., Weiss L. The role of the sinus wall in the passage of erythrocytes through the spleen. Blood 1973, 41:529-537.
16. Champion J.A., Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 2009, 26:244-249.
17. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008, 105:11613-11618.
18. Sharma G., Valenta D.T., Altman Y., Harvey S., Xie H., Mitragotri S., et al. Polymer particle shape independently influences binding and internalization by macrophages. J Control Release 2010, 147:408-412.
19. Geng Y., Dalhaimer P., Cai S., Tsai R., Tewari M., Minko T., et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007, 2:249-255.
20. Chauhan V.P., Popović Z., Chen O., Cui J., Fukumura D., Bawendi M.G., et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl 2011, 50:11417-11420.
21. Rolland J.P., Maynor B.W., Euliss L.E., Exner A.E., Denison G.M., DeSimone J.M. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc 2005, 127:10096-10100.
22. Jeong W., Napier M.E., DeSimone J.M. Challenging nature's monopoly on the creation of well-defined nanoparticles. Nanomedicine (Lond) 2010, 5:633-639.
23. Enlow E.M., Luft J.C., Napier M.E., DeSimone J.M. Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings. Nano Lett 2011, 11:808-813.
24. Zamboni W.C., Strychor S., Joseph E., Parise R.A., Egorin M.J., Eiseman J.L. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of Docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer Chemother Pharmacol 2008, 62:417-426.
25. Hou W., Watters J.W., McLeod H.L. Simple and rapid Docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 804:263-267.
26. Zamboni W.C., Combest A.J., DeLoia J.A., Edwards R.P., Bridges A.S., Zamboni B.A., et al. Pharmacologic and phenotypic study of Docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol 2011, 68:1255-1262.
27. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
28. Murugesan S., Ganesan S., Averineni R.K., Nahar M., Mishra P., Jain N.K. PEGylated poly(lactide-co-glycolide) (PLGA) nanoparticulate delivery of docetaxel: synthesis of diblock copolymers, optimization of preparation variables on formulation characteristics and in vitro release studies. J Biomed Nanotechnol 2007, 3:52-60.
29. Musumeci T., Ventura C.A., Giannone I., Ruozi B., Montenegro L., Pignatello R., et al. PLA/PLGA nanoparticles for sustained release of Docetaxel. Int J Pharm 2006, 325:172-179.
30. Senthilkumar M., Mishra P., Jain N.K. Long circulating PEGylated poly(D, L-lactide-co-glycolide) nanoparticulate delivery of Docetaxel to solid tumors. J Drug Target 2008, 16:424-435.
31. Dye D., Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br Med J 1980, 280:1353.
32. Kadoyama K., Kuwahara A., Yamamori M., Brown J.B., Sakaeda T., Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system AERS. J Exp Clin Cancer Res 2011, 30:93.
33. ten Tije A.J., Verweij J., Loss W.J., Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer therapy. Clin Pharmacokinet 2003, 42:665-685.